NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nexosome Oncology

Nexosome Oncology

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://nexosome.com/

Last Round

Seed

Nov 1, 2021

Total Funding Raised

$4M

Company Overview

Nexosome Oncology is a biotechnology company that develops blood tests for early-stage cancer detection using extracellular vesicle proteomics and AI/ML biomarker discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Application

Keywords

liquid biopsyearly cancer detectionexosome-based diagnosticsbiomarker discoveryproteomics platformextracellular vesicle proteomicsEV proteomicscancer diagnosticsnon-invasive diagnosticsAI biomarker discoverypatient stratificationtherapy response monitoringELISA immunoassaysdiagnostic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nexosome Oncology Comparables

Compare Nexosome Oncology with similar companies based on industry and business-model similarity.

Nexosome Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mursla Bio
78%
Mercy BioAnalytics
77%
Biological Dynamics, Inc.
71%

Nexosome Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 1, 2021

Key People

Founding team and executive leadership

Todd Hembrough

Chief Executive Officer

Executive Team

Nexosome Oncology Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2021

    $4M round with participation from DigiTx Partners and Esplanade Ventures.

Nexosome Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nexosome Oncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nexosome Oncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Year Founded2021
Last FundingNov 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.